Astrazeneca Submits Supplemental New Drug Applications For Seroquel XR For The Treatment Of Bipolar Mania And Bipolar Depression (Lufee.com)

Lufee categories

Astrazeneca Submits Supplemental New Drug Applications For Seroquel XR For The Treatment Of Bipolar Mania And Bipolar Depression
AstraZeneca announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.
- Discuss this news

Tell-a-friend about Lufee and this article

You are not logged in to Lufee at this moment. But you can tell a friend about this headline and send him an e-mail with your personal comment.

You still don't have a Lufee Account?

Sign up now and...

Get your personal account for free and sign up today. The sign up process will take you less than 5 minutes.

Signup here for free

Read what other users has to say

Nobody has posted a comment yet. Be the first to leave feedback on this news.

Read other headlines

UK drug crime strategy criticised
The government strategy for cutting drug-related crime is criticised in a report by the UK Drug Policy Commission.
Drug addicts 'should not be locked up'
Too many minor criminals with drug problems are being jailed and then receive poor treatment in prison, a damning report warns today.
The Count: Drug Tests as a Window on Workers
Drug Tests.
Cutting Dosage of Costly Drug Spurs a Debate
A drug for a rare enzyme deficiency can cost $300,000 a year, making the right dose a matter of public debate.

New users at Lufee